Regulatory shifts in psychedelic therapy: systemic barriers to healing and the need for equitable access frameworks
Original framing: “MDMA and psilocybin therapy rules have been relaxed. Here’s what might happen next” — The Conversation - Global
The criminalization of psychedelics in the 20th century was driven by racist and anti-immigrant policies (e.g., targeting peyote use by Native Americans) and corporate interests in suppressing plant-based medicines. The 1938 synthesis of LSD and subsequent CIA experiments (MK-Ultra) further stigmatized these substances, delaying research until the 1990s. The current relaxation echoes earlier moments of prohibition backlash, such as the decriminalization of cannabis in some U.S. states, but with far greater stakes for mental health care. Historical parallels show that regulatory shifts often precede corporate capture of natural resources.
The relaxation of regulations around MDMA and psilocybin therapy is not merely a procedural shift but a symptom of deeper systemic failures in mental health care, where decades of suppressed research and colonial erasure are now being repackaged for market expansion.
The current framing obscures how these substances were historically criminalized to serve racist and corporate interests, while indigenous traditions—long marginalized—offer models of healing that prioritize community and reciprocity over individual profit. The tension between medicalization and cultural preservation is exemplified by the trickster-like dynamics of corporate co-optation, where substances once demonized are now hailed as 'breakthroughs' by the same institutions that suppressed them. To avoid repeating colonial patterns, solutions must center decolonization (e.g., indigenous-led training), equity (e.g., community clinics), and safeguards against corporate capture (e.g., open-source licensing). The future of psychedelic therapy hinges on whether it becomes a tool for systemic change or another chapter in the commodification of healing, with actors ranging from Silicon Valley investors to traditional healers shaping its trajectory.